Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

6MW3211

Weili Zhao, Doctor

Saijuan Chen, Doctor

This study is a single arm, non-randomized, open label phase 2 international, multicenter clinical trial to evaluate preliminary efficacy and safety in subjects with relapsed or refractory lymphoma.

A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma

A Phase 2, Multicenter, Non-Randomized, Open-Label, Single-Arm Study to Evaluate the Preliminary Efficacy and Safety of 6MW3211 in Patients With Relapsed or Refractory Lymphoma

Defined as the percentage of subjects who experience a best response of either CR or PR

Defined as the percentage of subjects who experience a best response of CR

Time from the date of the first complete response (CR) or partial response (PR) to the earliest date of disease progression or death from any cause

Time from the date of first infusion to the date of confirmed CR or PR

Time from the date of first infusion to the earliest date of documented disease progression per radiological evidence or death from any cause

Time from the date of first infusion until the date of death from any cause

Mabwell (Shanghai) Bioscience Co., Ltd.

Respiratory Tract (Lung and Bronchial) Diseases

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

A non-randomized, open, Simon'soptimal2-stage study to evaluate the efficacy and safety of 6MW3211 in patients with advanced Lung Cancer who had failed therapy with PD-1/L1 Inhibitor.

36 to 64 patients with advanced lung cancer who failed pD-1 /L1 inhibitor treatment will be inrolled.

Cohort 1:20 to 33 patients with non-small cell lung cancer (NSCLC) Cohort 2:16 to 31 patients with small cell lung cancer (SCLC)

A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer

A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer Who Had Failed Therapy With PD-1/L1 Inhibitor

The percentage of (PR+CR) after treatment to the total number of cases was calculated

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Carcinoma

Carcinoma, Renal Cell

Kidney Neoplasms

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

single arm, non-randomized, multicenter, open label, phase 2 clinical trial in patients with advanced clear cell renal cacer

This study is a single arm, non-randomized, multicenter, open label, phase 2 clinical trial to evaluate preliminary efficacy and safety in patients with advanced clear cell renal cacer

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma	NCT05446688	Lymphoma	6MW3211	18 Years -	Mabwell (Shanghai) Bioscience Co., Ltd.
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer	NCT05431569	Advanced Lung C...	6MW3211	18 Years -	Mabwell (Shanghai) Bioscience Co., Ltd.
A Clinical Study of 6MW3211 in Patients With Renal Cancer	NCT05440045	Advanced Clear ...	6MW3211	18 Years - 75 Years	Mabwell (Shanghai) Bioscience Co., Ltd.

Spots Global Cancer Trial Database for 6mw3211

Every month we try and update this database with for 6mw3211 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for 6mw3211

Every month we try and update this database with for 6mw3211 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for 6mw3211 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.